Group 1 - The company Changshan Pharmaceutical held its sixth board meeting on December 30, 2025, to discuss the proposal for the absorption and merger of its wholly-owned subsidiary [1] - The meeting was conducted in a hybrid format, combining in-person attendance and remote voting [1] Group 2 - A new type of chip has been developed in China, which aims to bypass the restrictions imposed by lithography machines [1] - This new chip supports AI training and embodied intelligence and can be mass-produced using mature processes of 28 nanometers and above [1]

Core Viewpoint - Changshan Pharmaceutical (300255.SZ) plans to optimize its asset allocation and reduce management costs by absorbing its wholly-owned subsidiary, Hebei Meishan Polysaccharide Peptide Technology Co., Ltd. (Meishan Technology) [1] Group 1 - The absorption merger will result in the legal cancellation of Meishan Technology [1] - All business operations, assets, debts, and other rights and obligations of Meishan Technology will be inherited by the company [1]

证券代码：300255 证券简称：常山药业 公告编号：2025-53 河北常山生化药业股份有限公司 关于吸收合并全资子公司的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、吸收合并情况概述 河北常山生化药业股份有限公司（以下简称公司）于 2025 年 12 月 30 日召 开的第六届董事会第六次会议审议通过了《关于吸收合并全资子公司的议案》。 为进一步优化公司资产配置，降低管理成本，拟以公司为主体吸收合并全资子公 司河北梅山多糖多肽科技有限公司（以下简称梅山科技）。吸收合并完成后，梅 山科技将依法注销，梅山科技全部业务、资产、债权、债务及其他一切权利和义 务由公司依法承继。 本次吸收合并事项不构成关联交易，不构成《上市公司重大资产重组管理办 法》规定的重大资产重组。根据《深圳证券交易所创业板股票上市规则》《公司 章程》的相关规定，该事项属于公司董事会审批权限，无需提交股东会审议。 二、合并双方基本情况 （一）合并方基本情况 1．公司名称：河北常山生化药业股份有限公司 2．企业类型：其他股份有限公司（上市） 3．注册地址：中国（河北）自由贸易试验区正定 ...

会议以记名投票方式对各项议案进行表决，审议通过如下议案： 二、董事会会议审议情况 1．审议通过《关于吸收合并全资子公司的议案》 证券代码：300255 证券简称：常山药业 公告编号：2025-52 河北常山生化药业股份有限公司 第六届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 河北常山生化药业股份有限公司（以下简称公司）第六届董事会第六次会议 于 2025 年 12 月 30 日在公司办公楼会议室现场结合通讯表决的方式召开。本次 会议于 2025 年 12 月 26 日以邮件或直接送达的方式确保每一位董事收到本次会 议通知。与会的各位董事均已知悉与所议事项相关的必要信息。会议应参与表决 董事 6 名，实际参与表决董事 6 名。本次会议由公司董事长高晓东先生主持，符 合《公司法》及《公司章程》等规定。 1．第六届董事会第六次会议决议。 河北常山生化药业股份有限公司董事会 2025 年 12 月 30 日 公司通过整体吸收合并的方式合并全资子公司河北梅山多糖多肽科技有限 公司，合并完成后公司存续经营，河北梅山多 ...

Group 1 - The core viewpoint of the news is that Changshan Pharmaceutical's stock has experienced a decline, with significant trading activity and high financing levels, indicating potential investor concerns [1][2] - On December 29, Changshan Pharmaceutical's stock fell by 2.39%, with a trading volume of 743 million yuan. The net financing buy was negative at 1.09 million yuan, with a total financing balance of 2.628 billion yuan, accounting for 4.63% of the circulating market value [1] - The company has a high financing balance that exceeds the 90th percentile of the past year, indicating elevated levels of investor leverage [1] Group 2 - As of December 19, the number of shareholders in Changshan Pharmaceutical decreased by 4.57% to 39,600, while the average circulating shares per person increased by 4.79% to 23,203 shares [2] - For the period from January to September 2025, Changshan Pharmaceutical reported a revenue of 681 million yuan, a year-on-year decrease of 13.11%, and a net profit attributable to shareholders of -44.82 million yuan, a decline of 714.77% [2] - The company has distributed a total of 181 million yuan in dividends since its A-share listing, with 4.595 million yuan distributed over the last three years [3]

Core Viewpoint - The Shenzhen Stock Exchange indices will undergo sample adjustments effective from December 15, with significant changes in the constituent stocks of various indices [1] Group 1: Index Adjustments - The Shenzhen Component Index will replace 17 constituent stocks, adding 7 from the main board and 10 from the ChiNext [1] - The ChiNext Index will replace 8 constituent stocks [1] - The Shenzhen 100 Index will replace 7 constituent stocks, with 4 from the main board and 3 from the ChiNext [1] - The ChiNext 50 Index will replace 5 constituent stocks [1] Group 2: New Additions - New additions to the Shenzhen Component Index include Demingli, Wolong Nuclear Material, and Tuo Wei Information [1] - New additions to the ChiNext Index include Shuanglin Shares, Changshan Pharmaceutical, and Fulian Precision [1] - New additions to the Shenzhen 100 Index include Cangge Mining, Guohuo Aviation, and Dongshan Precision [1] - New additions to the ChiNext 50 Index include Changshan Pharmaceutical, Feilihua, and Xiechuang Data [1]

Group 1: Company Announcements - 蓝盾光电 announced the termination of the equity transfer agreement with Shanghai Xingsi Semiconductor, with no payment made for the equity transfer [1] - 兆新股份 plans to acquire 70% of Youde New Energy for a maximum price of 220 million yuan, enhancing its capabilities in the renewable energy operation sector [2] - 南都电源 is in the process of planning a change in control and has suspended its stock trading, with the suspension expected to last no more than two trading days [3] - 万科A reported a guarantee balance of 84.476 billion yuan as of October 31, with no overdue guarantee matters [4] - 国晟科技's stock price has increased significantly, with a cumulative rise of 206.62%, indicating potential irrational speculation and risks of a rapid price drop [5] - 中威电子 announced a change in its actual controller to Fu Yingbo, with stock trading set to resume [6] Group 2: Mergers and Acquisitions - 新兴铸管's subsidiary plans to acquire 100% of China Resources Steel for 1.244 billion yuan [7] Group 3: Share Transfers and Investments - 太龙药业's shareholder plans to transfer 50.1 million shares to Jiangyao Holdings [8] - 医药 approvals include 常山药业 receiving a drug registration certificate for heparin sodium injection in Turkmenistan [9] - 真兰仪表's shareholder intends to increase holdings by 10 to 20 million yuan [9] - 海南瑞泽's vice president plans to reduce holdings by 231,000 shares [9] - 金陵体育's director has reduced holdings by 0.0276% [9] - 佰仁医疗's subsidiary has received approval for a collagen implant product [9]

Group 1: ETF Market Growth - The scale of ETFs in the Shanghai market has surpassed 4.1 trillion yuan, with a year-to-date growth of 1.35 trillion yuan, representing a 50% increase [1] - The number of billion-yuan ETFs has increased by 36 this year, bringing the total to 80 [1] - The main drivers of this growth are the newly launched Shanghai Stock Exchange equity and bond series ETFs, with the Shanghai series index fund products exceeding 800 billion yuan, a 56% increase compared to the end of 2024 [1] Group 2: Bond Market Performance - Vanke's domestic bonds have generally declined, with "21 Vanke 06" dropping over 18% and other bonds like "21 Vanke 04" and "23 Vanke 01" also experiencing significant declines [1] Group 3: Cost Reduction in Fund Operations - Starting January 1, 2026, the registration and settlement fees for money market funds and ETFs will be reduced from 150,000 yuan per year to 120,000 yuan [1] - Additional fee reductions include halving the dividend distribution fees for B shares and depositary receipts in the Shanghai and Shenzhen markets [1] Group 4: Banking Sector Changes - Multiple banks, including Zheshang Bank and Chongqing Rural Commercial Bank, have announced plans to abolish their supervisory boards, with over 20 banks making similar announcements this year [2] - The responsibilities of the supervisory board will be transferred to the audit committee of the board of directors, aiming to enhance corporate governance efficiency [2] Group 5: Automotive Industry Performance - In November, China's automotive production exceeded 3.5 million units for the first time, marking a historical high, with total production and sales for the first 11 months surpassing 31 million units, both showing over 10% year-on-year growth [4] - New energy vehicle production and sales approached 15 million units, with a year-on-year increase of over 30%, and exports of new energy vehicles reached 2.315 million units, doubling year-on-year [4] Group 6: Component Market Trends - Domestic component prices continue to decline, with some companies starting to halt operations due to reduced orders, indicating a potential further decrease in component production [5] Group 7: Retail Sector Developments - Heytea has reportedly reduced its number of stores by over 600 within a year, shifting its focus from expansion to product quality amid an oversaturated market [5] Group 8: Corporate Actions - Zhaoxin Co. plans to acquire 70% of the equity of Youde New Energy for a maximum transaction price of 220 million yuan, positioning itself in the renewable energy operation sector [10] - MiniMax and Zhizhu are reportedly preparing for IPOs in Hong Kong, with potential fundraising in the hundreds of millions [9]

Group 1 - Pro Pharmaceutical has obtained a food production license for bat moth mycelium powder, categorized as a health food [1] - Zhongqi Co., Ltd. has had its application for issuing convertible bonds accepted by the Shenzhen Stock Exchange [2] - Baijun Medical's subsidiary has received approval for its collagen implant product, the first of its kind for facial dermal injections in China [3] Group 2 - Sinopharm Modern's subsidiary has received a drug registration certificate for Bumetanide injection, used for edema, hypertension, and preventing acute kidney failure [4] - Landun Optoelectronics has terminated the purchase of a stake in Star Si Semiconductor, with no payment made for the equity transfer [5] - Zhaoxin Co., Ltd. plans to acquire 70% of Youde New Energy for a maximum price of 220 million yuan, positioning it as a controlling subsidiary [6] Group 3 - Chongqing Rural Commercial Bank has had the qualifications of three non-executive directors approved, effective immediately [7] - Changshan Pharmaceutical has received a drug registration certificate for Heparin Sodium injection in Turkmenistan, used for anticoagulation [8] - Changshan Pharmaceutical's vice president has resigned for personal reasons but will continue to hold other positions within the company [9] Group 4 - Shaanxi Construction has won five major projects with a total bid amount exceeding 3.912 billion yuan, covering various sectors [10][11] - Huazhong Co., Ltd. reported a 1.6% month-on-month increase in pig sales revenue for November, with a total of 34.4 million yuan [12] - Yipin Hong's subsidiary has received a drug registration certificate for Levofloxacin oral solution, effective for treating various bacterial infections [13] Group 5 - Yabo Co., Ltd.'s subsidiary has won projects totaling 7.2933 million yuan, representing 2.13% of the company's audited revenue for 2024 [14] - Sunshine Nuohe plans to invest 20 million yuan in Biling Bio, acquiring a 2.0435% stake in the company focused on nanomedicine [15] - Jinzhi Technology has won projects totaling 76.172 million yuan, accounting for 4.3% of the company's projected revenue for 2024 [16]

Core Viewpoint - Changshan Pharmaceutical has experienced a continuous decline in the number of shareholders, indicating potential concerns regarding investor confidence and company performance [2] Shareholder Information - As of December 10, the number of shareholders for Changshan Pharmaceutical was 41,446, a decrease of 3,075 from the previous period (November 30), representing a decline of 6.91% [2] - This marks the third consecutive period of decline in the number of shareholders [2] Stock Performance - The closing price of Changshan Pharmaceutical was 68.32 yuan, reflecting an increase of 1.99% [2] - Since the concentration of shares began, the stock price has cumulatively increased by 9.93% [2] - The stock experienced 5 days of increases and 4 days of decreases during the reporting period [2] Financial Performance - For the first three quarters, the company reported total operating revenue of 681 million yuan, a year-on-year decrease of 13.11% [2] - The net profit for the same period was -44.82 million yuan, representing a significant year-on-year decline of 714.77% [2] - The basic earnings per share were reported at -0.0500 yuan [2]